Frustration at the pharmaceutical industry's high prices and secrecy bubbled over at the World Health Assembly this week as delegates fought for a strongly-worded resolution calling for greater transparency in the cost of clinical trials, drug R&D and prices. But some countries, including Canada, pushed for softer wording that could maintain secrecy in prices and research.
Post a Comment